Brain Health & Alzheimer’s Risk Assessment
earlier insight into cognitive health
Advances in blood-based testing now allow earlier assessment of Alzheimer’s disease risk and related neurodegenerative processes.
By combining biomarker analysis with genetic risk assessment, clinicians can better understand cognitive risk—often before significant symptoms develop.
What This Assessment Supports
Brain health testing can:
Estimate Alzheimer’s disease risk
Support early counseling and monitoring
Guide proactive planning and intervention
These tools provide a minimally invasive alternative to more complex diagnostic procedures and support informed decision-making around long-term brain health.
Testing Options for Brain Health & Alzheimer’s Risk Assessment
Advances in blood-based testing now allow earlier, less invasive assessment of Alzheimer’s disease risk and related neurodegenerative processes. At CMoC, brain health and Alzheimer’s risk assessment focuses on blood-based biomarkers, with genetic risk information used when appropriate, to help clinicians better understand cognitive risk—often before significant symptoms develop.
The blood-based testing options listed below are used to support risk stratification, early counseling, and proactive planning. When appropriate, results may help guide decisions about monitoring, lifestyle interventions, or next steps in evaluation. Your clinician will help determine which blood-based testing methods are appropriate based on your history, symptoms, and overall health goals.
These blood-based tests assess risk and disease-related biomarkers; they are not standalone diagnostic tests.
PrecivityAD by C2N - $300-$1750
PrecivityAD is a blood-based test that measures amyloid beta (Aβ42/40) ratios and tau protein levels using mass spectrometry, combined with age and APOE genotype, to generate an Amyloid Probability Score (APS).
This score estimates the likelihood of brain amyloid plaques consistent with Alzheimer’s disease pathology.
It offers clinicians a minimally invasive alternative to PET imaging, supporting earlier and more accurate diagnosis in patients with cognitive impairment.
APOE by LabCorp - billed to insurance or $175 OOP
The APOE genetic test identifies an individual’s Apolipoprotein E (APOE) alleles—ε2, ε3, and ε4—to assess inherited risk for developing Alzheimer’s disease.
Carrying one or two ε4 alleles is associated with increased susceptibility and earlier onset of Alzheimer’s, while ε2 may confer a protective effect.
This test helps stratify risk, inform preventive counseling, and interpret results from other Alzheimer’s biomarker tests such as PrecivityAD.
ATN Profile by LabCorp - billed to insurance or $600 OOP
A blood test that assesses biomarkers for Alzheimer's disease pathology by measuring levels of amyloid, tau, and neurofilament light chain (NfL) proteins. It serves as a tool to help physicians determine which patients may need further advanced testing for Alzheimer's, though it is not a definitive diagnostic test on its own. This profile provides a simpler, more accessible alternative to lumbar punctures for cerebrospinal fluid or expensive PET scans.
Plan Proactively for Brain Health
Understanding Alzheimer’s risk and brain health starts with choosing the right tests—and knowing how to interpret the results. Our clinicians will help you decide which testing options are appropriate and how the information can support thoughtful, proactive planning.